5-Amino-1MQ Overview, Dosing & Safety | Peptide Database

For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

5-Amino-1MQ

NNMT Inhibitor | Longevity & Metabolic Enhancement

Community Research

Join others researching 5-Amino-1MQ — share findings, ask questions, and learn from real experiences

5-Amino-1MQ is a small molecule NNMT (nicotinamide N-methyltransferase) inhibitor that enhances cellular NAD+ levels and mitochondrial function. Not a true peptide, but a small molecule compound used in longevity and metabolic optimization protocols.

Inhibits NNMT enzyme systemically, preventing NAD+ degradation and maintaining elevated cellular NAD+ levels to support mitochondrial function and metabolic processes.

Molecular Data

Research Indications

Significantly increases cellular NAD+ levels by inhibiting NNMT enzyme, supporting cellular energy production and DNA repair mechanisms essential for healthy aging.

Improves mitochondrial biogenesis and efficiency, enhancing cellular energy production and reducing oxidative stress markers associated with aging.

Enhanced NAD+ availability supports sirtuins and other longevity pathways involved in DNA repair, cellular maintenance, and stress resistance.

Improvement through enhanced mitochondrial efficiency.

Enhancement via cellular energy optimization.

Improved glucose/fat substrate switching.

Supports increased basal metabolic rate.

Improvements in fat burning capacity.

Dosing Protocols

Most common delivery method. Take with food to improve absorption and reduce potential GI effects. Consistent daily timing helps maintain steady NAD+ levels. Morning or early afternoon dosing preferred.

Conservative initiation

25mg

1x daily

Oral with food

Standard starting dose

50mg

Typical maintenance

75mg

Maximum dose

100mg

Split dosing protocol

2x daily

Oral with meals

Interactions

What to Expect

Side Effects & Safety

Common Side Effects

Generally minimal side effects

Occasional mild GI adjustment

Potential sleep interference if dosed late in day

Stop Signs - Discontinue if:

Severe gastrointestinal upset or persistent nausea

Unusual fatigue or weakness (opposite of expected effect)

Persistent headaches or dizziness

Sleep disturbances or insomnia

Allergic reactions (rash, swelling, difficulty breathing)

Significant mood changes or anxiety

Contraindications

Pregnancy or breastfeeding

Pre-existing metabolic conditions (consult healthcare provider)

Quality Checklist

Good Signs

White to off-white (or orange/amber for powder) appearance

Uniform color and size with clear labeling and batch information

Third-party testing certificates (COA) with >98% purity

Proper pharmaceutical packaging with moisture protection

Clear expiration dates and professional labeling

Warning Signs

Moisture damage or clumping may indicate degradation

Bad Signs

Sticky, discolored, or heat-damaged appearance

Unusual odor (should be relatively odorless)

Strong chemical odors indicating contamination

Cloudy reconstitution solution (injectables)

Frequently Asked Questions

What is the difference between the mcg and mg protocols for 5-Amino-1MQ injection?

Two vastly different dosing protocols exist differing by 100-200x: the mcg protocol uses 150-500mcg daily while the mg protocol uses ~350mg (5mg/kg) daily. This massive discrepancy creates serious overdose risk. Always verify units (mcg vs mg) before reconstitution to avoid a potentially 100+ fold dosing error.

Does 5-Amino-1MQ actually increase NAD+ levels in humans?

Animal studies demonstrate significant NAD+ elevation through NNMT inhibition. A 2024 study showed aged mice treated with 5A1MQ gained ~40% greater grip strength vs controls, with improved intramuscular lipid content and muscle fiber cross-sectional area, providing evidence that NAD+ enhancement translates to functional improvements.

Can I take 5-Amino-1MQ with food or does it need to be on an empty stomach?

Take 5-Amino-1MQ with food to improve absorption and reduce potential GI effects. Consistent daily timing helps maintain steady NAD+ levels, and morning or early afternoon dosing is preferred to avoid potential sleep interference.

What's the timeline for seeing metabolic benefits from 5-Amino-1MQ?

Week 1-2 shows gradual energy increase and mental clarity. Week 2-4 brings enhanced exercise performance and recovery. Week 4-8 shows improved metabolic markers and body composition changes. Peak longevity benefits with sustained cellular health improvements appear by week 8-12 with continuous use.

References

Diet-induced obese mice showed significant weight loss and adipocyte size reduction with 5-amino-1MQ treatment. Demonstrated that NNMT inhibition increases energy expenditure, reduces body weight and white adipose mass, improves insulin sensitivity, and normalizes glucose tolerance.

Demonstrated 38.4% oral bioavailability, half-life 6.9hr (oral) and 3.8hr (IV). Validated sensitive LC-MS/MS method for pharmacokinetic assessment supporting oral administration viability.

NNMTi-treated aged sedentary mice showed ~40% greater grip strength than controls. Combined with exercise, 60% grip strength increase. Also improved intramuscular lipid content and gastrocnemius fiber cross-sectional area.

Related Peptides

No known interactions; different mechanisms with potential complementary benefits.

Disclaimer

This information is for educational and research purposes only. Consult a healthcare professional before use.

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Key takeaways

Regulatory Status: Not FDA-approved for any indication. Preclinical research compound with no published human trials as of April 2026.
Research Stage: Preclinical (animal studies only); no completed or registered Phase 1, 2, or 3 human trials published as of April 2026.
Availability: Not available through Superpower. Distributed through gray-market research chemical vendors; not available by prescription from any licensed compounding pharmacy with established clinical protocols.
Prescribing information: No FDA-approved label exists. For context, see the ClinicalTrials.gov registry for NNMT inhibitor studies.
How it works: Inhibits NNMT, an enzyme that depletes S-adenosylmethionine (SAM) in adipose tissue, thereby shifting cellular metabolism toward fat oxidation and energy expenditure.
What preclinical studies show: In diet-induced obese mice, 5-Amino-1MQ reversed obesity and improved glucose tolerance; no published human data exists to confirm these effects translate to humans.
Because no human trials have been published, the evidence base for 5-Amino-1MQ consists entirely of animal studies and in vitro work. Preclinical findings in mice frequently do not replicate in humans, particularly in metabolic research, where multiple prior "promising" targets have failed at the human trial stage. Any use of this compound outside a supervised research setting carries unknown risks.

superpower.com

Research review and sources

Reviewed by: PeptideUniv Updated: March 26, 2026 Human trial evidence exists, but the practical takeaways still depend on population, endpoint, and how long the compound has been studied. Key research takeaways surfaced on this page Research context available in the underlying profile. Primary references and supporting sources Nicotinamide N-methyltransferase inhibition mitigates obesity-related metabolic dysfunction — Recent 5A1MQ preclinical paper covering obesity, glucose, and liver outcomes. Nicotinamide N-methyltransferase (NNMT): a novel therapeutic target for metabolic syndrome — Review article that explains the rationale for targeting NNMT in metabolic research.

Source: peptideuniv.com ↗

Practical and safety references

These excerpts are educational, not personalised medical instructions.

Dosage reference

5-Amino-1MQ Dosage Protocols

Standard Fat Loss Protocol 50 mg Once daily with food 8-12 weeks Accelerated Protocol 100 mg/day (50 mg twice daily) Twice daily with meals Metabolic Stack Protocol 50-100 mg/day oral Once or twice daily Standard Fat Loss Protocol: Start here to assess tolerance. Take with breakfast or lunch. Avoid taking late in the day on the off chance it affects sleep (rare but reported). Most users see gradual results starting around week 4. Accelerated Protocol: Split the dose between breakfast and lunch. This is the upper range commonly used. Do not exceed 100 mg/day without medical guidance. Better results when combined with regular exercise and a moderate caloric deficit. Metabolic Stack Protocol: When stacking with MOTS-c or a GLP-1 agonist, start at 50 mg/day and increase only if well tolerated. The combination targets multiple metabolic pathways simultaneously, so starting conservatively is wise. These are general guidelines for research purposes. Always consult a healthcare professional before use.

Source: peptidesexplorer.com ↗

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →